The CircaHealth CircaPain study protocol: A longitudinal multi-site study of the chronobiological control of chronic pain.

- 3 Doriana Taccardi¹, Hailey GM Gowdy¹, Lesley Singer², Jennifer Daly-Cyr², Amanda M Zacharias¹,
- 4 Zihang Lu³, Manon Choinière^{4,5}, M Gabrielle Pagé^{4,6}, Nader Ghasemlou^{1,7,8*}
- ⁵ ¹Department of Biomedical & Molecular Sciences, Queen's University; ²Chronic Pain Network,
- 6 McMaster University; ³Department of Public Health Sciences, Queen's University; ⁴Dept of
- 7 Anesthesioloy and Pain Medecine de l'Université de Montréal; ⁵Research Center of the Centre
- 8 hospitalier de l'Université de Montréal; ⁶Dept. of Psychology Research Center of the Centre hospitalier
- 9 de l'Université de Montréal, ⁷Department of Anesthesiology & Perioperative Medicine, Queen's
- 10 University; and ⁸Centre for Neuroscience Studies, Queen's University.
- 11

12 *Corresponding Author

- 13 Nader Ghasemlou, PhD
- 14 Pain Chronobiology & Neuroimmunology Laboratory
- 15 Queen's University
- 16 Botterell Hall, room 754
- 17 Kingston, Ontario, Canada K7L 3N6
- 18 email: nader.ghasemlou@queensu.ca
- 19 tel.: +1 613 533 6854

2	Λ
4	υ

21

- 22
- 23
- 24
- 24
- 25
- 23
- 26

27

Abstract

28 Introduction: One in five Canadians lives with chronic pain. Evidence shows that some individuals 29 experience pain that fluctuates in intensity following a circadian (24-hour) rhythm. Endogenous molecular 30 rhythms regulate the function of most physiological processes, neuroimmunology functions that govern 31 pain mechanisms. Addressing chronic pain rhythmicity on a molecular and biopsychosocial level can advance understanding of the disease and identify new treatment/management strategies. Our CircaHealth 32 33 CircaPain study uses an online survey combined with ecological momentary assessments and bio-sample 34 collection to investigate the circadian control of chronic pain and identify potential biomarkers. Our 35 primary objective is to understand inter-individual variability in pain rhythmicity, by collecting 36 biopsychosocial measures. The secondary objective accounts for seasonal variability and the effect of 37 latitude on rhythmicity.

Methods and analysis: Following completion of a baseline questionnaire, participants complete a series of electronic symptom-tracking diaries to rate their pain intensity, negative affect, and fatigue on a 0-10 scale at 8:00, 14:00, and 20:00 daily over 10 days. These measures are repeated at 6- and 12-months postenrolment to account for potential seasonal changes. Infrastructure is being developed to facilitate the collection of blood samples from subgroups of participants 2 times per day over 24-48 hours to identify rhythmic expression of circulating genes and/or proteins.

Ethics and dissemination: Ethical approval for this study was obtained by the Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board. Findings will be published in a relevant scientific journal and disseminated at national and international scientific meetings and online webinars. We maintain a website to post updated resources and engage with the community. We employ knowledge mobilization in the form of direct data sharing with participants. This study is funded by the Canadian Institutes of Health Research (CIHR) (grant PJT-497592) and the CIHR Strategy for Patient-Oriented Research (SPOR) Chronic Pain Network (CPN) (grant SCA-145102).

51 Ethical approval date: 08 March 2024

52 Estimated start of the study: April 2024

53 Keywords: chronic pain, epidemiology, circadian rhythm, biomarkers

54

55 Strengths and limitations of this study

- Data will be collected using self-report questionnaires only, which may lead to random or
 systematic misreporting.
- The online nature of the study might affect the diversity in our sample (e.g., the representation of
 rural and/or underprivileged communities).
- Physical distance from research laboratories with specialized equipment for analyses and
 biobanking storage might affect accessibility, however, this can be overcome by using mailable
 dried blood spot collection kits as described.
- Questionnaires used in our study have previously been validated in the chronic pain population
 and used in several languages.
- Uncovering distinct pain rhythmicity patterns and health outcomes associated with rhythmicity
 may help develop new treatments for different chronic pain conditions tailored to individual
 circadian rhythms.
- 68

Figure 1 caption: Design and protocol for the CircaHealth CircaPain study. The study is divided into three parts: a baseline assessment (t0) and two follow-up measures at 6 (t1) and 12 months (t2) after the initial assessment. Each assessment includes a battery of questionnaires and a 10-day e-diary, as well as the collection of biological samples.

73

74 1. Introduction

Chronic pain (lasting >3 months)(1) affects more than 1 in 5 individuals(2-4) and accounts for 5.9% of total disability-adjusted life years(5). While multidisciplinary treatments are recognized as the gold standard for pain management(6-9), the underlying mechanisms contributing to its chronicity are largely unknown and the few therapeutic options available offer only mild to moderate benefits(10, 11).

Biopsychosocial factors modulate individuals' pain experience and cause variability in the presentation and evolution of disease, leading to heterogeneity in treatment responses(12-15). A better understanding of how each person experiences pain may aid the development of new individualized

strategies for pain management(14, 16-18). A commonly used method to identify temporal variations in self-reported measures is the ecological momentary assessment (EMA)(19, 20). In recent years, intraindividual variability has been identified as an important aspect to consider, rather than conceptualized as noise(21). For example, chronic neuropathic pain (e.g., diabetic neuropathy) is observed to increase over the course of the day(22) while inflammatory pain syndromes (e.g., osteoarthritis) tend to follow an inverse pattern(23). However, these studies have not investigated specifically inter-individual differences within the same condition or examined biopsychosocial components associated with pain rhythmicity.

89 Chronobiology examines the contribution of time to biological outcomes including daily, lunar, 90 and seasonal changes. Circadian rhythms help to align physiological functions with the external 91 environment via external cues including light and feeding schedules (24). These rhythms are controlled 92 by a set of core clock genes that orchestrate a tightly regulated transcription-translation feedback loop 93 lasting approximately 24 hours(25). The timing of secreted factors (e.g., melatonin, cortisol, and growth 94 hormone) is regulated by the suprachiasmatic nucleus, which communicates with peripheral clocks located 95 in almost all organs and cells in the body. These circulating factors interact with immune cells, resulting 96 in a bidirectional circadian-immune relationship(26). Evidence across species supports the influence of 97 circadian rhythms on biopsychosocial processes and behaviours(27).

98 Capturing fluctuations in pain intensity and their associated factors (both psychosocial and 99 molecular), as reported by people with chronic pain, is central to a thoughtful clinical assessment of 100 disease. These fluctuations may themselves provide insight into underlying causes and result in a better 101 understanding of how persistent pain is modulated. We use a methodology that includes psychosocial 102 measures and provides a foundation for biological sample collection to identify pain rhythmicity 103 phenotypes and their associated molecular signatures. Our core multidisciplinary team includes clinical 104 researchers, pain clinicians, biostatisticians, basic scientists, and individuals with lived experience. This 105 study will characterize inter-individual differences in pain experience and identify new biomarkers of pain 106 rhythmicity.

107

108 **2.** Methods and analysis

109 **2.1 Primary outcome**

110 The primary outcome of this study is to identify phenotypes of pain rhythmicity using ecological

111 momentary assessment and determine their association with biopsychosocial profiles in individuals living

112 with chronic pain across Canada.

113 **2.2 Secondary outcome**

- 114 The secondary outcome of this study is to identify characteristics of pain rhythmicity and determine their
- associations with the geophysical and seasonal environments of participants.

116 **2.3 Study Design**

117 A biopsychosocial approach underpins this longitudinal cohort study (figure 1). This study complies with

118 STROBE guidelines(28) and with the principles of the Declaration of Helsinki(29).

119 2.3.1 Patient and Public Involvement

Patient partners (LS and JDC) were involved in the research design from study outset via the CIHR-SPOR Chronic Pain Network. All research questions and outcome measures were developed in collaboration with patient partners, taking into account their priorities and experiences with chronic pain. This was done through consultations with the research team which occur every month. Patient partners contribute to the knowledge translation and dissemination efforts by helping the research team summarise the research objectives and background in clear user-friendly language and ensure that the information is accessible to a public audience.

127 **2.4 Participants**

128 **2.4.1** Inclusion and exclusion criteria

Individuals with any self-reported chronic pain condition (pain lasting >3 month(30), irrespective of formal diagnosis) who are eligible to participate in the study and complete the survey if: they are at least 18 years old, have internet access, can read, comprehend, and record information written in English or French (or any other languages the survey may be validated in). Individuals reporting a history of travel in the past 2 weeks or planning to travel in a different time zone over the course of the study are excluded to reduce any confounding effects of travel-related circadian disruption ('jet lag').

135 2.4.2 Sample Size and power calculation

We aim to recruit \geq 2500 participants within Canada. A subset of participants (n=1000) will be re-contacted for the collection of blood samples to accompany their survey data, to amass 800 participants compliant with epidemiological data and blood collection requirements, allowing for a 20% dropout rate.

139 Based on our unpublished results, we detect four major pain phenotypes (constant low, constant high, 140 rhythmic, and mixed patterns; at an approximate ratio of $\sim 1:1:1:1$). Mean and standard deviation for each 141 primary variable were obtained from this preliminary data. The sample size calculation used analysis of 142 variance (ANOVA) assuming a type I error $\alpha = 0.05$, and type II error $\beta = 0.2$ (i.e. 80% power). To detect 143 a difference in pain score and physical function between circadian phenotypes, we will require at least 48 144 males and 64 females per pain rhythmicity phenotype; to detect changes in rhythmic genes between 145 phenotypes will require at least 20 males and 28 females. We, therefore, collect blood and biopsychosocial 146 data from n=80 males/112 females, \sim 200 participants per pain phenotype via online surveys/EMA. Thus, 147 our sample is sufficiently powered to detect significant changes between circadian phenotypes for each 148 sex.

149 **2.5 Recruitment procedures**

We administer a battery of demographic and clinical self-report questionnaires and daily e-diaries to examine circadian fluctuations in pain. The e-diaries employ an EMA approach which collects repeated measurements of the same participants as they go about their daily lives(31). We collect biological samples (blood) at least 2 times within $a \ge 12$ -hour period to examine protein profile differences among people with chronic pain. After analysis of location-related data, we aim to expand data collection internationally, validating and translating the survey outside the Canadian population to address latitudinal features.

Passive recruitment strategies are used to reach potential participants. Permission to advertise the study either via social media (Facebook, X, etc.) or in paper form on-site (e.g., poster, handouts) is obtained from interested organizations and will follow their local requirements (e.g., request form, local Research Ethics Board approval, etc.). These could include 1) relevant departments/clinics within partner clinical and community outreach sites (e.g., family health teams, physiotherapy clinics, etc.); 2) specialized pain clinics; or 3) pain advocacy organizations such as PainBC, Association québécoise de la douleur

162 chronique, the People in Pain Network, and the Pain Society of Alberta. Recruitment is also coordinated163 through partner clinical sites.

164 Participants can access the survey independently from any device with internet capability. Eligibility 165 screening and informed consent are embedded in the survey and need to be completed before accessing 166 questionnaires. Research team members at partner clinical sites may offer a mobile device (via registered 167 mail) to the participants with Wi-Fi access who do not have a mobile device. Settings on the device will 168 be locked from the user, except for web browsing and Wi-Fi connection access. Currently, validated self-169 report measures and EMA e-diary are available in English and French. Therefore, the study will be 170 accessible to a majority of Canadians. Furthermore, people who opt-in for blood sample donation will be 171 contacted by the research team and consent after being informed about collection procedures.

To investigate our secondary outcome regarding geophysical location, seasonality, and pain rhythmicity, we will collect information on 1) seasonality via repetition of the study measures (6-12 months followups) and 2) geolocation within Canada and subsequent international expansion (first 3 digits of the postal code). Additional validated translations of questionnaires needed for international expansion will be uploaded to the local Research Ethics Board (REB) for review and approval.

177 **2.6 Data collection procedures**

Eligible and consented participants are asked to complete questionnaires and e-diaries using their preferred mobile device or home computer, starting the next morning of enrolment. All epidemiological data collection tools are hosted on the platform Research Electronic Data Capture (REDCap)(32, 33), which also facilitates data storage.

182 **2.6.1 Self-report questionnaire battery**

Self-report questionnaire battery includes scales/questions covering different domains, based on recommendations from NIH Task Force on reporting chronic low back pain studies(34) and IMMPACT(35, 36): pain and fatigue, affect and other psychological characteristics and physical activity levels (see Table 1). Sociodemographic data and existing medical conditions other than chronic pain are also collected. Participants are asked to complete this questionnaire battery in an online form via a link to the REDCap survey or supported by research staff (see supplementary for English and French versions of

189 the questionnaires). Once completed, participants receive a confirmation email and instructions for the 190 next steps to complete the 10-day e-diary.

191 **2.6.2 10-day e-diary**

192 Using the ecological momentary assessment (EMA) approach(19); the e-diary assesses 7 domains at 3 193 established timepoints (08:00, 14:00, 20:00) for 10 days. The domains are: 1) pain; 2) fatigue; 3) anxiety; 194 4) sadness; 5) physical activity; 6) sleep quality and 7) changes in daily medication intake. For pain, 195 participants are asked, "How much pain do you feel right now" (0 = no pain, 10= worst pain imaginable). Similar numerical rating scales or a brief Likert scale are used to assess the other domains (full measures 196 197 in appendix). A question on sleep quality is included in the 08:00 diary and a question on changes in usual 198 medication intake is included at each time point (see Supplemental Materials for examples of the e-diary 199 monitoring tool in English and French). Invitations and reminders to complete the e-diary are sent either 200 via email or SMS text according to participants' preference. Notifications are sent respectively at 08:00, 201 14:00, and 20:00 with a reminder 30 minutes later.

202 2.6.3 Follow-up measures

Participants will be asked to complete the same measures (self-report questionnaire battery and 10-day ediary) at 6 and 12 months after initial enrolment to assess seasonality changes. The surveys will be automatically sent to the same account used to complete baseline measures.

206 2.6.4 Biomarker candidates

207 2.6.4.1 Biosample collection

208 Participants can consent to be contacted for the collection of biological samples. Infrastructure for blood 209 collection is under development. Blood samples will be taken from participants across a \geq 12-hour period, 210 with at least 2 blood draws (e.g., 1 taken in the range 07:00-10:00, 1 taken in the range 19:00-22:00). Once 211 biological sample collection commences, optimal tools (accounting for both feasibility and reliability) will 212 be used and may include the collection of whole blood in K₂EDTA and Tempus RNA tubes at 213 collaborating clinical sites or mailable dried blood spot collection kits (e.g., Telimmune DUO Plasma Separation cards, West Lafayette, IN, USA) for participants to complete at home. Biological sample 214 215 collection methods will be uniform across partner sites and are dependent on available and validated

216 technology at the time of launch. Specific methods for biological sample collection and analysis will be 217 included in future publications.

218 **2.6.4.2** Biosample processing and storage

219 Depending on available technology at the time of collection, samples will be processed according to best 220 practices associated with individual tools. Blood will be prepared for long-term storage at \leq -80°C, with 221 the potential for future proteomic, transcriptomic, and/or lipidomic analyses.

222 **2.6.4.3 Bioinformatics**

After processing biosamples with the aforementioned analyses, established bioinformatics pipelines will be used. For example, we will evaluate, align, and assemble raw RNA sequencing reads with FastQC(37), Hisat2(38), and StringTie(39), as appropriate. Comparative bioinformatics analysis can then be used to identify genes, transcripts, proteins, and pathways of interest by mining weighted gene coexpression network analysis (WGCNA), as previously done(40-46).

228 2.7 Data management

Any symptom diary containing ≥ 5 days with submitted diaries at all time points over the 10-day period will be used in the analyses(47); all other symptom diaries will be excluded from main analyses and may be used for secondary analyses. Diary entries completed >1 hour past the time of collection will be excluded from analysis and labelled as 'timed out'. Any duplicate report for a given report time will be discarded, with only the original dataset used.

234 **2.8** Statistics and data analyses

Epidemiological data will be used to identify biopsychosocial determinants of pain and other variables of rhythmicity. Descriptive statistics will be used to characterize the study population. Additionally, the severity of relevant symptomatology reported across sessions will be compared using descriptive and inferential statistics. Our primary outcome is to assess whether there is a change in rhythmicity phenotypes — measured using 10-day e-diary — in both groups from baseline to follow-ups. Clustering of participants based on EMA will be repeated at baseline and follow-up. Participants with distinct rhythmicity trajectories (i.e., pain phenotypes) are identified by EMA scores using a latent class mixed effect model

242 (LCMM, based on *lcmm* R package (48)), a probabilistic modelling algorithm approach that clusters 243 longitudinal data accounting for correlation between repeated measures(49) and has been used to 244 characterize pain chronicity over months(50). To ensure we discover biologically meaningful phenotypes, 245 in addition to LCMM, functional data analysis with high-dimensional data clustering (based on *funHDDC*) 246 R package(51)) will be considered as an alternative approach, which allows for participants with similar 247 pain fluctuation phenotypes to be clustered together. Graphical tools (e.g., Sankey plot) will be used to 248 visualize changes in phenotype. Latent transition analysis will be applied to study the probability of 249 transition of an individual from one phenotype to another phenotype from baseline to follow-ups(52, 53). 250 Furthermore, we will use linear mixed-effect models(54, 55) to test for differences in average pain scores 251 in the morning vs evening across time points. All analyses will be performed halfway through and at the 252 end of the study recruitment.

Our secondary outcome is to assess whether changes in rhythmicity phenotypes from baseline to followup post-intervention and from different geographical locations (e.g., Eastern vs Pacific time zones, across latitudes) will correspond to changes in biopsychosocial factors measured using our self-report battery. We will use descriptive statistics to characterize the study population (e.g. Fisher's Exact tests, chi-square, Kruskal-Wallis) where appropriate and we will run regression models to assess any difference between baseline and follow-ups. Once available, blood samples (RNA, protein, etc.) will be analyzed to identify molecular and cellular characteristics of pain rhythmicity.

All statistical analyses will be performed using R(56) or SPSS(57) where appropriate.

261 **3. Ethics and dissemination**

262 This study complies with STROBE guidelines(28) and with the principles of the Declaration of 263 Helsinki(29). The CircaHealth CircaPain project and its associated procedures have been reviewed and 264 approved by the Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics 265 Board (DBMS-160-23). Knowledge translation efforts include sharing findings at national and 266 international scientific meetings and online webinars. In addition, we maintain a website (CircaPain) and 267 an X (Twitter) page to post updated resources (blogs, videos, research updates, etc.) and engage with 268 people who live with chronic pain, clinicians, and others interested in the topic. We employ knowledge 269 mobilization in the form of direct data sharing with participants: at the time of consent, participants can

opt-in to receive their data upon study completion. They will receive a user-friendly pain report generated
using their own data from the 10-day e-diaries after completion of follow-ups to prevent any bias.

272 4. Discussion

273 This study design adopts the biopsychosocial model of chronic pain through its use of both psychosocial 274 measures and the collection of biological samples for a personalized and precision medicine approach to 275 identifying potential biomarkers of disease. A multidisciplinary approach is adopted to study inter-276 individual variability in pain rhythmicity and its associated psychosocial and molecular factors. We 277 consider fluctuations in pain intensity across time(58), which constitutes an important aspect to take into 278 account in the treatment of chronic pain(21). Indeed, pain intensity is reported to fluctuate over the course 279 of a week and the extent of this variability scores seem to be heterogeneous across participants but stable 280 over assessment periods(59). Recent reviews have shown the importance of several factors when 281 considering pain variability, including weather, seasonality, and genetic variants among others(60, 61). 282 However, there is still an important gap in our knowledge in understanding the causes of this 283 variability(59). New data from preclinical models and analysis of biomarkers in the clinic show a neuro-284 immune axis in chronic pain. For example, immune cells exhibit rhythmic changes in the blood with 285 increasing numbers during the day peaking in late evening/night(62). Thus, collection of blood samples 286 at different times of day will provide important information regarding rhythmic changes in circulating 287 mediators over time that may affect pain outcomes. Underlying chronobiological and immune 288 mechanisms contributing to pain chronicity will be addressed, providing a crucial aspect in the 289 development of new interventions and preventive measures for chronic pain(10).

290 The data collected from this longitudinal cohort will identify psychosocial factors and changes in 291 genes/proteins associated with pain rhythmicity in people living with any type of chronic pain. Participants 292 are assessed using a baseline battery of questionnaires and e-diary measures over a 10-day period, which 293 are repeated in follow-up assessments. The baseline assessment employs a modified version of the NIH 294 minimum dataset for research in chronic low back pain (63, 64) to capture key biopsychosocial variables 295 (e.g., pain, fatigue, affect). Furthermore, blood sample collection from this cohort will enable the creation 296 of a chronobiological biobank to analyze the neuroimmune signatures of participants with chronic pain 297 conditions. Any blood samples collected will be banked for future transcriptomic, proteomic, metabolomic 298 and/or lipidomic analysis.

299 Investigating the impact of pain rhythmicity on psychosocial and neuroimmune outcomes in a 300 clinical population will aid in the identification of novel biopsychosocial markers of chronic pain. Our 301 focus on circadian rhythms as a potential biomarker for pain chronicity represents a novel approach. We 302 consider 1) biopsychosocial factors associated with pain variability and chronobiological rhythmicity; 2) 303 immune cell rhythms and gene expression to identify specific profile and their association with 304 psychosocial outcomes; and 3) seasonality and geophysical location factors that might contribute to pain 305 variability. This interdisciplinary strategy will increase our understanding of mechanisms driving chronic 306 pain and associated psychosocial factors and help identify therapeutic targets acting on the circadian clock 307 or non-pharmacological options that address the circadian control of pain.

308 Author contributions:

All authors conceptualized the study. DT was in charge of the study design and wrote the original draft version. DT, HGMG, MGP, NG, and MC were in charge of the inclusion/exclusion criteria and defined how the study would be carried out. DT, HGMG, AMZ, and ZL were in charge of the definition of the data analysis methodology and the statistics, including sample size calculations. LS and JDC contributed to the ethics and dissemination sections. All authors contributed to background research. DT, HGMG, and NG were in charge of the ethics approval process. All authors contributed to the revision of the study. All authors read and approved the final manuscript.

316 **Funding statement**

317 This research is funded by a Canadian Institutes of Health Research (CIHR) project grant (PJT-497592)

to NG and MGP, and a sub-grant from the CIHR Strategy for Patient Oriented Research (SPOR) Chronic

319 Pain Network (SCA-145102) to NG. MGP is a Junior 2 research scholar from the Fonds de recherche du

320 *Québec en santé.*

321 Competing interests statement

322 None of the authors has competing interests related to this manuscript.

323 Acknowledgments

324 We would like to thank the funding sources for supporting this project.

325 References

326 Treede R-D, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. Chronic pain as a symptom 1. 327 or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases 328 (ICD-11). Pain. 2019;160(1):19-27. 329 Dahlhamer J, Lucas J, Zelaya C, Nahin R, Mackey S, DeBar L, et al. Prevalence of Chronic Pain 2. 330 and High-Impact Chronic Pain Among Adults - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(36):1001-6. 331 332 Shupler MS, Kramer JK, Cragg JJ, Jutzeler CR, Whitehurst DGT. Pan-Canadian Estimates of 3. 333 Chronic Pain Prevalence From 2000 to 2014: A Repeated Cross-Sectional Survey Analysis. J Pain. 334 2019;20(5):557-65. 335 Ferreira ML, de Luca K, Haile LM, Steinmetz JD, Culbreth GT, Cross M, et al. Global, regional, 4. 336 and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: a 337 systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(6):e316-338 e29. 339 5. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and 340 territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 341 2020;396(10258):1204-22. 342 Gatchel RJ, McGeary DD, McGeary CA, Lippe B. Interdisciplinary chronic pain management: 6. 343 past, present, and future. Am Psychol. 2014;69(2):119-30. 344 Flor H, Fydrich T, Turk DC. Efficacy of multidisciplinary pain treatment centers: a meta-analytic 7. 345 review. Pain. 1992;49(2):221-30. 346 8. Ospina M, Harstal C. Multidisciplinary Pain Programs for Chronic Pain: Evidence from 347 systematic reviews. Alberta Heritage Foundation for Medical Research - Health Technology 348 Assessment. Alberta, Canada2003. p. 1-48. 349 9. Pain IAftSo. Taks Force on Guidelines for Desirable Characteristics for Pain Treatment 350 Facilities. IASP. Desirable characteristics for pain treatment facilities. http://www.IASP-351 pain.org/desirabl.htlm. 1990. 352 10. Campbell F, Hudspith M, Choinière M, El-Gabalawy H, Laliberté J, Sangster M, et al. Working 353 Together to Better Understand, Prevent, and Manage Chronic Pain: What We Heard. Ottawa, ON, 354 Canada: Health Canada; 2020. 355 11. Campbell F, Hudspith M, Anderson M, Choinière M, El-Gabalawy H, Laliberté J, et al. Chronic 356 Pain in Canada: Laying a Foundation for Action. A report by the Canadian Pain Task Force, June 2019. 357 Ottawa, ON: Health Canada; 2019. 358 Bell L, Cornish P, Gauthier R, Kargus C, Rash J, Robbins R, et al. Implementation of the Ottawa 12. 359 Hospital Pain Clinic stepped care program: A preliminary report. Can J pain. 2020;4(1):168-78. 360 Coghill RC. Individual differences in the subjective experience of pain: new insights into 13. 361 mechanisms and models. J Headache Pain. 2010;50(9):1531-5. Edwards RR, Dworkin RH, Turk DC, Angst MS, Dionne R, Freeman R, et al. Patient 362 14. 363 phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain. 364 2016;157(9):1851. 365 15. Fillingim RB. Individual differences in pain: understanding the mosaic that makes pain personal. 366 Pain. 2017;158(Suppl 1):S11. 367 Aili K, Campbell P, Michaleff ZA, Strauss VY, Jordan KP, Bremander A, et al. Long-term 16. 368 trajectories of chronic musculoskeletal pain: a 21-year prospective cohort latent class analysis. Pain. 369 2021;162(5):1511.

370 17. Bäckryd E, Persson EB, Larsson AI, Fischer MR, Gerdle B. Chronic pain patients can be 371 classified into four groups: Clustering-based discriminant analysis of psychometric data from 4665 372 patients referred to a multidisciplinary pain centre (a SORP study). PLoS One. 2018;13(2):e0192623. 373 Gaynor SM, Bortsov A, Bair E, Fillingim RB, Greenspan JD, Ohrbach R, et al. Phenotypic 18. 374 profile clustering pragmatically identifies diagnostically and mechanistically informative subgroups of 375 chronic pain patients. Pain. 2021;162(5):1528-38. 376 Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin 19. 377 Psychol. 2008;4:1-32. 378 20. Schneider S, Junghaenel DU, Broderick JE, Ono M, May M, Stone AA. II. Indices of Pain 379 Intensity Derived From Ecological Momentary Assessments and Their Relationships With Patient 380 Functioning: An Individual Patient Data Meta-analysis. J Pain. 2021;22(4):371-85. 381 Lester HF, Cullen-Lester KL, Walters RW. From nuisance to novel research questions: Using 21. multilevel models to predict heterogeneous variances. Organ Res Methods. 2019:1-47. 382 383 22. Hu S, Gilron I, Singh M, Bhatia A. A Scoping Review of the Diurnal Variation in the Intensity 384 of Neuropathic Pain. Pain Med. 2022;23(5):991-1005. 385 Treister R, Honigman L, Lawal OD, Lanier RK, Katz NP. A deeper look at pain variability and 23. 386 its relationship with the placebo response: results from a randomized, double-blind, placebo-controlled 387 clinical trial of naproxen in osteoarthritis of the knee. Pain. 2019;160(7):1522-8. 388 Lavtar P, Rudolf G, Maver A, Hodžić A, Starčević Čizmarević N, Živković M, et al. Association 24. 389 of circadian rhythm genes ARNTL/BMAL1 and CLOCK with multiple sclerosis. PloS one. 390 2018;13(1):e0190601. 391 De Somma E, Jain RW, Poon KWC, Tresidder KA, Segal JP, Ghasemlou N. Chronobiological 25. 392 regulation of psychosocial and physiological outcomes in multiple sclerosis. Neurosci Biobehav Rev. 393 2018;88:73-83. 394 Cermakian N, Lange T, Golombek D, Sarkar D, Nakao A, Shibata S, et al. Crosstalk between the 26. 395 circadian clock circuitry and the immune system. Chronobiology Int. 2013;30(7):870-88. 396 27. Rivkees SA. The Development of Circadian Rhythms: From Animals To Humans. Sleep Med 397 Clin. 2007;2(3):331-41. 398 28. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The 399 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: 400 guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495-9. 401 29. World Medical Association Declaration of Helsinki: ethical principles for medical research 402 involving human subjects. JAMA. 2013;310(20):2191-4. 403 Aziz O, Giamberardino MA, Barke A, Korwisi B, Baranowski AP, Wesselmann U, et al. The 30. 404 IASP classification of chronic pain for ICD-11: chronic secondary visceral pain. Pain. 2019;160(1):69-405 76. Stone AA, Shiffman S. Capturing momentary, self-report data: a proposal for reporting 406 31. 407 guidelines. Ann Behav Med. 2002;24(3):236-43. 408 32. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap 409 consortium: Building an international community of software platform partners. J Biomed Inform. 410 2019;95:103208. 411 33. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data 412 capture (REDCap)--a metadata-driven methodology and workflow process for providing translational 413 research informatics support. J Biomed Inform. 2009;42(2):377-81. 414 Deyo RA, Dworkin SF, Amtmann D, Andersson G, Borenstein D, Carragee E, et al. Report of 34. 415 the NIH Task Force on research standards for chronic low back pain. J Pain. 2014;15(6):569-85.

416 35. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et al. Core outcome

417 domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106(3):337-45.

418 36. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core

419 outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1-2):9420 19.

421 37. FASTQC. A quality control tool for high throughput sequence data [Internet]. 2010. Available
422 from: <u>https://www.bioinformatics.babraham.ac.uk/projects/fastqc/</u>.

- 423 38. Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and 424 genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37(8):907-15.
- 425 39. Pertea M, Pertea GM, Antonescu CM, Chang T-C, Mendell JT, Salzberg SL. StringTie enables
 426 improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 2015;33(3):290-5.
- 427 40. Ahmadi SA, Tranmer JE, Ritonja JA, Flaten L, Topouza DG, Duan QL, et al. DNA methylation
 428 of circadian genes and markers of cardiometabolic risk in female hospital workers: An exploratory
 429 study. Chronobiol Int. 2022;39(5):735-46.
- 430 41. Choi J, Tantisira KG, Duan QL. Whole genome sequencing identifies high-impact variants in 431 well-known pharmacogenomic genes. Pharmacogenomics J. 2019;19(2):127-35.
- 432 42. Choi J, Topouza DG, Tarnouskaya A, Nesdoly S, Koti M, Duan QL. Gene networks and
 433 expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous
 434 ovarian cancer. BMC Cancer. 2020;20(1):413.
- 435 43. Duan QL, Lasky-Su J, Himes BE, Qiu W, Litonjua AA, Damask A, et al. A genome-wide 436 association study of bronchodilator response in asthmatics. Pharmacogenomics J. 2014;14(1):41-7.
- 437 44. Miliku K, Duan QL, Moraes TJ, Becker AB, Mandhane PJ, Turvey SE, et al. Human milk fatty 438 acid composition is associated with dietary, genetic, sociodemographic, and environmental factors in the
- 439 CHILD Cohort Study. Am J Clin Nutr. 2019;110(6):1370-83.
- 440 45. Ritonja JA, Aronson KJ, Flaten L, Topouza DG, Duan QL, Durocher F, et al. Exploring the 441 impact of night shift work on methylation of circadian genes. Epigenetics. 2021:1-10.
- 442 46. Topouza DG, Choi J, Nesdoly S, Tarnouskaya A, Nicol CJB, Duan QL. Novel MicroRNA443 Regulated Transcript Networks Are Associated with Chemotherapy Response in Ovarian Cancer. Int J
 444 Mol Sci. 2022;23(9).
- 445 47. Wrzus C, Neubauer AB. Ecological Momentary Assessment: A Meta-Analysis on Designs,
 446 Samples, and Compliance Across Research Fields. Assessment. 2023;30(3):825-46.

447 48. Proust-Lima C, Philipps, V., & Liquet, B. Estimation of Extended Mixed Models Using Latent

- 448 Classes and Latent Processes: The R Package lcmm. J Stat Softw. 2017;78(2):1-56.
- 449 49. Lu Z, Lou W. Bayesian approaches to variable selection: a comparative study from practical 450 perspectives. Int J Biostat. 2021;18(1):83-108.
- 451 50. Dunn KM, Jordan K, Croft PR. Characterizing the course of low back pain: a latent class 452 analysis. Am J Epidemiol. 2006;163(8):754-61.
- 453 51. Bouveyron C, Jacques J. funHDCC: Model-based clustering in group-specific functional
 454 subspaces. R package version 10 [Internet].
- 455 52. Abarda A, Dakkon M, Azhari M, Zaaloul A, Khabouze M. Latent Transition Analysis (LTA) : A
- 456 Method for Identifying Differences in Longitudinal Change Among Unobserved Groups. Procedia
- 457 Comput Sci. 2020;170:1116-21.
- 458 53. Nguena Nguefack HL, Pagé MG, Katz J, Choinière M, Vanasse A, Dorais M, et al. Trajectory
- Modelling Techniques Useful to Epidemiological Research: A Comparative Narrative Review ofApproaches. Clin Epidemiol. 2020;12:1205-22.

- 461 54. Luke SG. Evaluating significance in linear mixed-effects models in R. Behav Res Methods.
 462 2017;49(4):1494-502.
- 463 55. Martinez-Huertas JA, Olmos R, Ferrer E. Model Selection and Model Averaging for Mixed-
- 464 Effects Models with Crossed Random Effects for Subjects and Items. Multivariate Behav Res.
 465 2022;57(4):603-19.
- 466 56. Team RC. R: A language and environment for statistical computing. R Foundation for Statistical
- 467 Computing, Vienna, Austria. Vienna, Austria: R Foundation for Statistical Computing; 2021.
 468 57. Corp. I. IBM SPSS Statistics for Macintosh, Version 28.0. Armonk, NY: IBM Corp2021.
- 469 58. Kongsted A, Kent P, Axen I, Downie AS, Dunn KM. What have we learned from ten years of
- 470 trajectory research in low back pain? BMC Musculoskelet Disord. 2016;17:220.
- 471 59. Pagé MG, Gauvin L, Sylvestre M-P, Nitulescu R, Dyachenko A, Choinière M. An Ecological
- 472 Momentary Assessment Study of Pain Intensity Variability: Ascertaining Extent, Predictors, and
- Associations With Quality of Life, Interference and Health Care Utilization Among Individuals Living
 With Chronic Low Back Pain. J Pain. 2022;23(7):1151-66.
- 475 60. Horvath G, Nagy K, Tuboly G, Nagy E. Pain and weather associations Action mechanisms; 476 personalized profiling. Brain Res Bull. 2023;200:110696.
- 477 61. Mogil JS. Sources of Individual Differences in Pain. Annu Rev Neurosci. 2021;44:1-25.
- 478 62. Sennels HP, Jørgensen HL, Hansen A-LS, Goetze JP, Fahrenkrug J. Diurnal variation of
- hematology parameters in healthy young males: the Bispebjerg study of diurnal variations. Scand J Clin
 Lab Invest. 2011;71(7):532-41.
- 481 63. Lacasse A, Roy JS, Parent AJ, Noushi N, Odenigbo C, Page G, et al. The Canadian minimum
- dataset for chronic low back pain research: a cross-cultural adaptation of the National Institutes of
 Health Task Force Research Standards. CMAJ Open. 2017;5(1):E237-E48.
- 484 64. Angarita-Fonseca A, Pagé MG, Meloto CB, Gentile EL, Léonard G, Massé-Alarie H, et al. The
- 485 Canadian version of the National Institutes of Health minimum dataset for chronic low back pain
- 486 research: reference values from the Quebec Low Back Pain Study. Pain. 2023;164(2):325-35.
- 487

